Literature DB >> 24413818

Comment on "secondary chemoprevention of localized prostate cancer by short-term androgen deprivation to select indolent tumors suitable for active surveillance: a prospective pilot study".

A de la Taille1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24413818     DOI： 10.1007/s00345-013-1234-9

Source DB:  PubMed          Journal:  World J Urol        ISSN： 0724-4983            Impact factor:   4.226


× No keyword cloud information.
  8 in total

1.  TOOKAD(®) Soluble vascular-targeted photodynamic (VTP) therapy: determination of optimal treatment conditions and assessment of effects in patients with localised prostate cancer.

Authors:  Abdel-Rahmène Azzouzi; Eric Barret; Caroline M Moore; Arnaud Villers; Clare Allen; Avigdor Scherz; Gordon Muir; Michel de Wildt; Neil J Barber; Souhil Lebdai; Mark Emberton
Journal:  BJU Int       Date:  2013-10       Impact factor: 5.588

2.  Effect of dutasteride on the risk of prostate cancer.

Authors:  Gerald L Andriole; David G Bostwick; Otis W Brawley; Leonard G Gomella; Michael Marberger; Francesco Montorsi; Curtis A Pettaway; Teuvo L Tammela; Claudio Teloken; Donald J Tindall; Matthew C Somerville; Timothy H Wilson; Ivy L Fowler; Roger S Rittmaster
Journal:  N Engl J Med       Date:  2010-04-01       Impact factor: 91.245

3.  EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and treatment of clinically localised disease.

Authors:  Axel Heidenreich; Joaquim Bellmunt; Michel Bolla; Steven Joniau; Malcolm Mason; Vsevolod Matveev; Nicolas Mottet; Hans-Peter Schmid; Theo van der Kwast; Thomas Wiegel; Filliberto Zattoni
Journal:  Eur Urol       Date:  2010-10-28       Impact factor: 20.096

4.  Impact of comorbidity on survival among men with localized prostate cancer.

Authors:  Peter C Albertsen; Dirk F Moore; Weichung Shih; Yong Lin; Hui Li; Grace L Lu-Yao
Journal:  J Clin Oncol       Date:  2011-02-28       Impact factor: 44.544

5.  Duration of androgen suppression in the treatment of prostate cancer.

Authors:  Michel Bolla; Theodorus M de Reijke; Geertjan Van Tienhoven; Alphonsus C M Van den Bergh; Jorg Oddens; Philip M P Poortmans; Eliahu Gez; Paul Kil; Atif Akdas; Guy Soete; Oleg Kariakine; Elsbietha M van der Steen-Banasik; Elena Musat; Marianne Piérart; Murielle E Mauer; Laurence Collette
Journal:  N Engl J Med       Date:  2009-06-11       Impact factor: 91.245

6.  Whole-gland ablation of localized prostate cancer with high-intensity focused ultrasound: oncologic outcomes and morbidity in 1002 patients.

Authors:  Sebastien Crouzet; Jean Yves Chapelon; Olivier Rouvière; Florence Mege-Lechevallier; Marc Colombel; Hélène Tonoli-Catez; Xavier Martin; Albert Gelet
Journal:  Eur Urol       Date:  2013-04-30       Impact factor: 20.096

7.  Advanced prostate cancer treated with intermittent or continuous androgen deprivation in the randomised FinnProstate Study VII: quality of life and adverse effects.

Authors:  Arto J Salonen; Kimmo Taari; Martti Ala-Opas; Jouko Viitanen; Seppo Lundstedt; Teuvo L J Tammela
Journal:  Eur Urol       Date:  2012-07-27       Impact factor: 20.096

8.  Long-term survival of participants in the prostate cancer prevention trial.

Authors:  Ian M Thompson; Phyllis J Goodman; Catherine M Tangen; Howard L Parnes; Lori M Minasian; Paul A Godley; M Scott Lucia; Leslie G Ford
Journal:  N Engl J Med       Date:  2013-08-15       Impact factor: 91.245
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.